Back to Top
Go Back
Journal Photo for Cancer Letters
Peer reviewed only Open Access

Cancer Letters (CL)

Publisher : Elsevier
Cancer Research Molecular Biology Oncology
Claim Your Journal Get PRC Visit Website
e-ISSN 1872-7980
p-ISSN 0304-3835
Issue Frequency Continuously
Impact Factor 16.7
Est. Year 1975
Mobile 204853911
Country Netherlands The
Language English
APC YES
Impact Factor Assignee Google Scholar
Email Min-Li@ouhsc.edu

Journal Descriptions

An international journal providing a forum for original and pertinent contributions in cancer research Cancer Letters is an international journal that considers full-length articles and Mini Reviews in the broad area of basic and translational oncology. Additionally, Special Issues highlight topical areas in cancer research. Basic areas of interest to a broad readership of Cancer Letters include the molecular genetics and cell biology of cancer, radiation biology, molecular pathology, hormones and cancer, viral oncology, metastasis, and chemoprevention. The journal places emphasis on experimental therapeutics, particularly targeted therapies for personalized cancer medicine, including metronomic chemotherapy. Benefits to authors We also provide many author benefits, such as free PDFs, a liberal copyright policy, special discounts on Elsevier publications and much more. Please click here for more information on our author services.

Cancer Letters (CL) is :-

  • International, Peer-Reviewed, Open Access, Refereed, Cancer Research, Molecular Biology, Oncology, Medicine, Biochemistry , Online or Print , Continuously Journal

  • UGC Approved, ISSN Approved: P-ISSN P-ISSN: 0304-3835, E-ISSN: 1872-7980, Established: 1975, Impact Factor: 16.7
  • Does Not Provide Crossref DOI

  • Indexed in: Scopus, PubMed

  • Not indexed in WoS, DOAJ, UGC CARE

Indexing

Publications of CL

Novel potent azetidine-based compounds irreversibly inhibit Stat3 activation and induce antitumor response against human breast tumor growth in vivo
Nagendra Verma, May, 2022
Signal transducer and activator of transcription (Stat)3 is a valid anticancer therapeutic target. We have discovered a highly potent chemotype that amplifies the Stat3-inhibitory activity o...